To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Details

Instance of

clinical trial

Start time

1 October 2020

End time

1 October 2022

Country

United States

Main subject

paclitaxel

clinical trial phase

phase II clinical trial

maximum age

90

minimum age

18

number of participants

0

research intervention

paclitaxel

research subject recruitment status

withdrawn

study type

interventional study

title

An Open Label Phase II Study to Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer